Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy
January 11, 2021 07:00 ET
|
Akouos, Inc.
The Resonate™ program provides access to a potential genetic diagnosis by offering genetic testing at no cost to eligible individuals, their insurance, or their healthcare providersA genetic diagnosis...
Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020 09:00 ET
|
Akouos, Inc.
BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 12, 2020 07:00 ET
|
Akouos, Inc.
- Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO - - Continued progress towards 2021 IND submission for AK-OTOF, a gene therapy...
Akouos Announces Key Leadership Appointments
October 01, 2020 07:00 ET
|
Akouos, Inc.
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos to Present at Upcoming October Virtual Investor Conferences
September 24, 2020 08:00 ET
|
Akouos, Inc.
BOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos to Present at Cantor Global Virtual Healthcare Conference
September 08, 2020 08:00 ET
|
Akouos, Inc.
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights
August 13, 2020 07:00 ET
|
Akouos, Inc.
- Upsized IPO in June 2020 raised $244.4 million in gross proceeds - - Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF...
Akouos Announces Expansion of Executive Team and Board of Directors
August 05, 2020 08:00 ET
|
Akouos, Inc.
Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos,...
Akouos to Present at BTIG Virtual Biotechnology Conference
August 03, 2020 08:00 ET
|
Akouos, Inc.
BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live...
Akouos Announces Closing of Initial Public Offering
June 30, 2020 16:05 ET
|
Akouos, Inc.
BOSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve,...